ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 151 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $56,594 | -74.0% | 35,594 | +2.0% | 0.00% | -100.0% |
| Q4 2022 | $217,346 | +2.5% | 34,887 | +10.3% | 0.00% | 0.0% |
| Q3 2022 | $212,000 | +12.8% | 31,624 | +7.1% | 0.00% | +100.0% |
| Q2 2022 | $188,000 | +41.4% | 29,517 | +2.9% | 0.00% | 0.0% |
| Q1 2022 | $133,000 | +84.7% | 28,678 | +99.3% | 0.00% | – |
| Q4 2021 | $72,000 | -58.4% | 14,388 | +0.1% | 0.00% | -100.0% |
| Q3 2021 | $173,000 | -44.4% | 14,368 | -2.3% | 0.00% | 0.0% |
| Q2 2021 | $311,000 | -26.5% | 14,710 | -2.5% | 0.00% | 0.0% |
| Q1 2021 | $423,000 | +8.2% | 15,089 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $391,000 | -32.0% | 15,049 | -2.8% | 0.00% | -66.7% |
| Q3 2020 | $575,000 | -29.2% | 15,480 | -2.2% | 0.00% | -25.0% |
| Q2 2020 | $812,000 | +72.0% | 15,833 | +5.7% | 0.00% | +33.3% |
| Q1 2020 | $472,000 | -50.1% | 14,984 | -5.5% | 0.00% | -25.0% |
| Q4 2019 | $945,000 | +63.8% | 15,851 | +0.7% | 0.00% | +100.0% |
| Q3 2019 | $577,000 | -21.8% | 15,745 | -0.7% | 0.00% | -33.3% |
| Q2 2019 | $738,000 | +25.9% | 15,854 | +8.7% | 0.00% | +50.0% |
| Q1 2019 | $586,000 | -15.4% | 14,591 | -3.1% | 0.00% | -33.3% |
| Q4 2018 | $693,000 | +2.8% | 15,064 | -0.8% | 0.00% | +50.0% |
| Q3 2018 | $674,000 | +15.4% | 15,180 | +1.8% | 0.00% | 0.0% |
| Q2 2018 | $584,000 | -27.0% | 14,907 | +34.8% | 0.00% | -33.3% |
| Q1 2018 | $800,000 | +6.2% | 11,061 | -3.2% | 0.00% | +50.0% |
| Q4 2017 | $753,000 | +33.5% | 11,430 | +1.5% | 0.00% | 0.0% |
| Q3 2017 | $564,000 | +31.8% | 11,257 | +21.6% | 0.00% | 0.0% |
| Q2 2017 | $428,000 | +37.6% | 9,256 | +5.0% | 0.00% | +100.0% |
| Q1 2017 | $311,000 | +201.9% | 8,814 | +7.1% | 0.00% | – |
| Q4 2016 | $103,000 | -99.9% | 8,230 | -0.3% | 0.00% | – |
| Q3 2016 | $114,290,000 | +40.4% | 8,252 | +0.1% | 0.00% | – |
| Q2 2016 | $81,411,000 | -38.3% | 8,240 | +5.9% | 0.00% | -100.0% |
| Q1 2016 | $132,000,000 | -22.8% | 7,784 | +1.3% | 0.00% | 0.0% |
| Q4 2015 | $171,000,000 | +93856.0% | 7,684 | -0.2% | 0.00% | 0.0% |
| Q3 2015 | $182,000 | -100.0% | 7,698 | +0.1% | 0.00% | -66.7% |
| Q2 2015 | $628,653,000 | +75.9% | 7,689 | +99.2% | 0.00% | +200.0% |
| Q1 2015 | $357,343,000 | +128.9% | 3,859 | -0.0% | 0.00% | 0.0% |
| Q4 2014 | $156,098,000 | +110.1% | 3,860 | +27.1% | 0.00% | – |
| Q3 2014 | $74,285,000 | +54.3% | 3,037 | -0.1% | 0.00% | – |
| Q2 2014 | $48,154,000 | +2.3% | 3,040 | -2.3% | 0.00% | – |
| Q1 2014 | $47,069,000 | +12.8% | 3,113 | +2.5% | 0.00% | – |
| Q4 2013 | $41,742,000 | – | 3,038 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |